Vitrisia Therapeutics

Vitrisia Therapeutics is a New York-based biotechnology company focused on developing innovative, long-acting therapies for retinal diseases. The company was founded by the leadership team behind Iveric Bio, including Dr. David Guyer and Glenn Sblendorio, following Iveric's acquisition by Astellas. Vitrisia's primary mission is to address the high unmet need in conditions such as Geographic Atrophy (GA) and neovascular Age-related Macular Degeneration (nAMD). Their approach utilizes proprietary sustained-release delivery systems designed to provide durable efficacy and significantly reduce the frequency of intravitreal injections. By focusing on small molecule therapeutics, the company aims to improve patient compliance and long-term visual outcomes. Vitrisia is currently in the pre-clinical stage, advancing a pipeline of candidates targeting key pathological pathways in the eye.